Company: SINT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024040
Chunk: 37

Company: Sintx Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 37
---
 decreased $0.7 million, or 85% as compared to the same period in
2024.

Revenue
trends and strategic focus

The decrease in total revenue for the two periods was primarily due to
the Company’s ongoing strategic repositioning away from non-core, low-margin OEM technical manufacturing contracts that did not
support long-term profitability. This planned reduction in OEM-related revenue is consistent with our corporate shift toward commercializing
proprietary silicon nitride-based biomedical devices, which we believe offer stronger margins, a more defensible competitive position,
and better long-term value for shareholders.

While this strategic realignment has led to a temporary minor decline in
reported revenue, we believe it is a necessary step in positioning the Company for sustainable growth. During this transitional period,
we continue to invest in the development and regulatory advancement of silicon nitride-based orthopedic and surgical implants, as evidenced
by our recently submitted 510(k) for osteotomy wedges used in foot and ankle fusion procedures. We believe that these products will serve
as key revenue drivers in the future.

Cost
of revenue and Gross profit

For
the three months ended June 30, 2025, cost of revenue decreased $0.1 million, or 58%, compared to the same period in 2024 primarily due
to the decrease in revenue mentioned above.

For
the six months ended June 30, 2025, cost of revenue decreased $0.1 million, or 24%, compared to the same period in 2024 primarily due
to the decrease in revenue mentioned above.

Research
and development expenses

For
the three months ended June 30, 2025, research and development expenses decreased $0.4 million, or 26%, compared to the same period in
2024, primarily due to a decrease in payroll related costs.

For
the six months ended June 30, 2025, research and development expenses decreased $1.3 million, or 36%, compared to the same period in
2024, primarily due to a decrease in payroll related costs, patent expenses, protypes, and outside consulting costs.

General
and administrative expenses

For
the three months ended June 30, 2025, general and administrative expenses increased $0.2 million, or 22%, compared to the same
period in 2024, primarily due to fees paid to departing members of the Board of Directors, higher
accounting expenses, partially offset by lower legal expenses.

For